



Request under Freedom of Information Act 2000

Request Ref: NGFOI 18/19: 472

Thank you for your request for information received at Northampton General Hospital NHS Trust (NGH) on 29/11/2018.

I am pleased to be able to provide you with the following information:

1. *I have a Freedom of Information request with regards to the usage of Biologics and Biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months (latest 12 months possible) with the following drugs?*

For period 01/12/2017 – 30/11/2018

Number of patients treated	Rheumatoid Arthritis	Ankylosing Spondylitis	Psoriatic Arthritis	Psoriasis	Crohns Disease	Ulcerative Cloitis
TOTAL						
Abatacept (Orencia)	13	0	0	0	0	0
Adalimumab (Biosimilar)	0	0	0	0	0	0
Adalimumab (Humira)	70	37	37	20	65	16
Apremilast (Otezla)	0	0	26	25	0	0
Baricitinib (Olumiant)	49	0	0	0	0	0
Brodalumab (Kyntheum)	0	0	0	*≤5	0	0
Certolizumab (Cimzia)	*≤5	*≤5	*≤5	0	0	0
Dimethyl Fumarate (Skilarence)	0	0	0	9	0	0
Etanercept (Enbrel)	23	*≤5	*≤5	*≤5	0	0
Etanercept Biosimilar (Benepali or Erelzi)	123	42	36	12	0	0
Golimumab (Simponi)	14	12	17	0	0	*≤5
Guselkumab (Tremfya)	0	0	0	*≤5	0	0

Infliximab (Remicade)	0	0	0	*≤5	0	*≤5
Infliximab Biosimilar (Inflectra, Remsima or Flixabi)	8	*≤5	*≤5	0	78	49
Ixekizumab (Taltz)	0	0	*≤5	*≤5	0	0
Rituximab (Mabthera)	*≤5	0	0	0	0	0
Rituximab Biosimilar (Rixathon or Truxima)	74	0	0	0	0	0
Sarilumab (Kevzara)	0	0	0	0	0	0
Secukinumab (Cosentyx)	0	11	8	6	0	0
Tildrakizumab (Ilumetri)	0	0	0	0	0	0
Tocilizumab (Ro Actemra)	34	0	0	0	0	0
Tofacitinib (Xeljanz)	*≤5	0	*≤5	0	0	0
Ustekinumab (Stelara)	0	0	*≤5	27	*≤5	0
Vedolizumab (Entyvio)	0	0	0	0	9	27

*In accordance with the Freedom of Information Act, Exemption section 40 (Personal Information) has been applied. Due to the low numbers involved, 5 or fewer, we have withheld the exact numbers to protect the identities of individuals.